BridgeBio beat investor expectations with 1,028 unique prescriptions for ATTR-CM therapy Attruby, setting the company up to ...

These various tests are at different stages of validation – assuring they’re accurate across many different populations. And, for each protein, there are several different met ...

Now, several publications and presentations at the recent Alzheimer’s Association International Conference have demonstrated that blood tests measuring amyloid and tau proteins have become much more ...

In recent years, a growing number of scientific studies have backed an alarming hypothesis: Alzheimer's disease isn't just a ...

A Potential Solution for Neurodegenerative Diseases. Open Access Library Journal, 12, 1-16. doi: 10.4236/oalib.1112714 . Alzheimer’s Disease (AD), a complex neurodegenerative condition, significantly ...

Alzheimer’s disease — which affects an estimated 7 million Americans — is notoriously difficult to detect, especially in its ...

More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...

Explore AC Immune's innovative Alzheimer's and Parkinson's therapies, key pharma collaborations, and financial outlook. Learn more on ACIU stock here.

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...

A man who should have developed early-onset Alzheimer's disease due to a genetic mutation is still symptom-free in his 70s.

Researchers from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) have found that tau protein and beta-amyloid – two pathological hallmarks of Alzheimer’s disease – ...

Altered cerebrospinal fluid (CSF) levels of amyloid-β (Aβ) and tau proteins have been found in PDD, with intermediate changes for Aβ42 in non-demented PD. The authors investigated whether AD-related ...